Article Text

PDF
Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases
  1. Raul Velez-Montoya1,
  2. José Luis Guerrero-Naranjo1,
  3. Carmen Cecilia Gonzalez-Mijares1,
  4. Jans Fromow-Guerra1,
  5. George R Marcellino2,
  6. Hugo Quiroz-Mercado3,
  7. Virgilio Morales-Cantón1
  1. 1Retina Department, Asociación para Evitar la Ceguera en México IAP, México DF
  2. 2OptiMedica Corporation, Santa Clara, California, USA
  3. 3Denver Health Medical Center, Department of Ophthalmology, School of Medicine, University of Colorado, Colorado, USA
  1. Correspondence to Dr Raul Velez-Montoya, Retina Department, Asociación para Evitar la Ceguera en México IAP, Vicente García Torres #46, San Lucas Coyoacan, Coyoacan 04030, México DF; rvelezmx{at}yahoo.com

Abstract

Background/aims The pattern scan laser photocoagulator (PASCAL) is a novel laser device that uses 10–30 ms pulse duration for retina photocoagulation. The aim of this study was to analyse the safety profile of this approach.

Methods This was a retrospective study. We reviewed the clinical records of all laser sessions performed with PASCAL from November 2007 to July 2008. Where there were any complications, we recorded the laser parameters, type, affected retina region, postoperative interval and treatment if required.

Results There were 1301 consecutive cases. Complications included 17 cases of retinal bleeding (1.3%), two cases of choroidal detachment (0.15%) and one case of exudative retinal detachment (0.07%). There was no statistical difference between the laser parameters used in patients with or without complications.

Conclusion The laser parameters for PASCAL are safe. The complications and adverse effects encountered in this series are similar to those reported in other studies.

  • Complications
  • diabetic retinopathy, panretinal photocoagulation
  • pattern scan laser
  • PASCAL
  • retina
  • treatment lasers

Statistics from Altmetric.com

Footnotes

  • Funding The study was completely sponsored by the hospital research program.

  • Competing interests GRM is employed by OptiMedica Corporation and has a proprietary interest in the PASCAL Photocoagulator. The remaining authors do not have financial or economic interest on the publication of this manuscript.

  • Patient consent Obtained.

  • Ethics approval The study was conducted according the tenets of the Declaration of Helsinki and was also approved by the ethics committee of our institution, which depends directly on the Ministry of Health.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.